Research programme: antibody-based cancer therapies - Medarex/Oxford BioTherapeutics

Drug Profile

Research programme: antibody-based cancer therapies - Medarex/Oxford BioTherapeutics

Alternative Names: OX-003; OX-025

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Medarex; Oxford Genome Sciences
  • Developer Oxford BioTherapeutics
  • Class Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 09 May 2014 Preclinical trials in Non-small cell lung cancer in United Kingdom (Parenteral)
  • 09 May 2014 Preclinical trials in Small cell lung cancer in United Kingdom (Parenteral)
  • 28 Sep 2009 Research is ongoing in the USA and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top